

# The United Kingdom's first NHS Endobarrier service for advanced diabetes: 1-year outcomes for all 62 treated patients

ROBERT EJ RYDER, SUSAN P IRWIN, WYN BURBRIDGE, HARDEEP GANDHI, TAHIRA BASHIR, RACHAEL A ALLDEN, MORDEL WILSON, MELANIE WYRES, MELISSA CULL, MAHI YADAGIRI, JOHN P BLEASDALE, EDWARD N FOGDEN, MARK R ANDERSON, PIYA SEN GUPTA

## Abstract

**Aims:** EndoBarrier is a 60 cm proximal intestinal liner, endoscopically implanted for up to 1 year, designed to mimic the bypass aspect of Roux-en-Y gastric bypass surgery. We aimed to assess its safety and efficacy in patients with advanced diabetes.

**Methods:** Since October 2014 we have implanted 62 EndoBarriers in our NHS service. By November 2018 all were explanted. Outcomes were monitored in a registry.

**Results:** In 61 of the 62 patients (98.4%) (age 51.4±7.2 years, 54.1% male, 57.4% Europid, diabetes duration 12.0 (8.0–19.5) years, 57.4% insulin-treated, BMI 41.9±7.4 kg/m<sup>2</sup>) with implant and explant data, mean±SD HbA<sub>1c</sub> fell by 23.7±21.4 mmol/mol from 80.2±22.5 to 56.5±11.5 mmol/mol ( $p<0.001$ ), weight fell by 15.9±8.5 kg from 122.6±27.9 to 106.7±28.9 kg ( $p<0.001$ ), systolic blood pressure from 138.5±15.0 to 125.8±14.6 mmHg ( $p<0.001$ ), cholesterol from 4.7±1.4 to 3.9±0.9 mmol/L ( $p<0.001$ ) and alanine aminotransferase (a marker for non-alcoholic fatty liver disease) from 33.2±19.8 to 19.5±11.4 U/L ( $p<0.001$ ). In the 35 insulin-treated patients, median (IQR) insulin dose reduced from 100 (54–140) to 40 (0–70) units ( $p<0.001$ ), with 10/35 (28.6%) discontinuing insulin. There were significant falls (UKPDS Risk Engine v2) in the risk of coronary heart disease (CHD) and stroke, suggesting that EndoBarrier treatment in 100 such patients could prevent 8 events of CHD or stroke and save 6 lives over the 10 years. Ten of the 62 patients (16%) required early removal (4 for gastrointestinal haemorrhage, 2 for liver abscess, 1 for another intra-abdominal abscess and 3 for gastrointestinal symptoms). All made a full recovery following

device removal and most derived benefit despite early removal.

**Conclusion:** EndoBarrier was highly effective in this setting in patients with advanced diabetes and obesity. Given the high cardiovascular and microvascular risk of these patients, benefits might outweigh risks. As an endoscopic procedure it is relatively simple and non-invasive. Early removal rates require monitoring and there needs to be increased focus on preventing complications but, on balance, EndoBarrier deserves further investigation as a potential treatment for wider use.

*Br J Diabetes* 2019;19:110-117

**Key words:** EndoBarrier, duodenal-jejunal bypass liner, DJBL, obesity, type 2 diabetes, diabetes, bariatric surgery

## Introduction

### Background and rationale

EndoBarrier<sup>®</sup> (GI Dynamics, Boston, USA), also known as the duodenal-jejunal bypass liner, is a 60 cm long impermeable fluoropolymer sleeve which is implanted by endoscopy into the first part of the small intestine where it remains for up to 1 year (Figure 1). It is held in place by a nitinol anchor, such that food passes through it without coming into contact with the small intestine, thereby interfering with the normal digestive processes that occur in this region. Pancreatic and bile secretions mix with the undigested nutrients at the distal end of the EndoBarrier. Thus, it mimics the bypass aspect of Roux-en-Y gastric bypass surgery.<sup>1-6</sup> The endoscopic insertion and removal of EndoBarrier are day case procedures, performed in less than an hour, usually under general anaesthesia. This form of reversible bariatric procedure has been shown to reduce weight and improve glycaemic control in patients with diabetes and obesity.<sup>2-6</sup>

REVISE-Diabetes (Randomisation to EndoBarrier alone Versus with Incretin analogue in SustainEd Diabetes), an Association of British Clinical Diabetologists (ABCD) UK-funded, multicentre, randomised controlled trial (ISRCTN00151053) led by our institution supports these observations. Additionally, preliminary data on the first year of treatment with the EndoBarrier device combined with liraglutide therapy showed benefit on HbA<sub>1c</sub> and weight/body

Sandwell & West Birmingham NHS Trust, City Hospital, Birmingham, UK

**Address for correspondence:** Dr Bob Ryder


Sandwell & West Birmingham NHS Trust, City Hospital, Dudley Road, Birmingham B18 7QH, UK

Tel: 0121 507 4591

E-mail: bob.ryder@nhs.net

<https://doi.org/10.15277/bjd.2019.226>

**Figure 1.** The Endobarrier device (A) and a diagram of the device in situ (B)



mass index (BMI) and liver fat.<sup>7-9</sup> Despite the growing evidence of benefits, EndoBarrier treatment has not been tried as part of a routine diabetes NHS service.

There is currently a worldwide pandemic of type 2 diabetes. The International Diabetes Federation (IDF) describes this as 'a global emergency'.<sup>10</sup> Type 2 diabetes is driven by obesity.<sup>11</sup> Management comprises a lifestyle programme focused on weight loss achieved through education with changes to diet and increased exercise. If target levels for glycaemic control are not achieved, pharmacological options include metformin, sulfonylureas, pioglitazone, metglinides, alpha glucosidase inhibitors, DPP4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists; beyond these medications, insulin can be initiated.<sup>12,13</sup> In view of insulin resistance, which is a feature of type 2 diabetes, high doses may be required.<sup>14</sup> The use of insulin, however, is associated with increase in weight,<sup>15,16</sup> which is counterintuitive in patients who are already obese. Bariatric/metabolic surgery is a proven alternative option in this situation.<sup>17-19</sup> A less established and less invasive option for achieving temporary proximal intestinal bypass is with the use of the EndoBarrier device. The advantages of this approach include the lack of permanence of the intervention rather than permanent changes to the anatomy, with lesser invasiveness and no open wounds following surgery. In view of these advantages, many patients express a preference for this procedure.

We aimed to evaluate whether the experience acquired through the REVISE-Diabetes study could translate into establishment of a safe and effective NHS EndoBarrier service for patients with sub-optimally controlled type 2 diabetes and obesity. In order to establish the service we aimed to:

- design a comprehensive 2-year patient pathway
- consult with relevant teams and patients
- obtain management support
- agree funding system with local service commissioners
- prime patients to maintain improvements after device removal by suggesting institution of behaviour changes during EndoBarrier treatment
- establish a secure online registry<sup>20</sup> to monitor outcomes prospectively

Once established, we aimed to audit the impact of EndoBarrier therapy on weight, BMI, HbA<sub>1c</sub>, systolic blood pressure, cholesterol, HDL cholesterol, cardiovascular risk as assessed by the UKPDS Risk Engine v2,<sup>21</sup> alanine aminotransferase as a marker of liver fat,<sup>9</sup> daily insulin dose and insulin discontinuation rate. We also aimed to audit the rate of serious adverse events and early removal due to side effects.


## Methods

### Study design and setting

We designed a comprehensive 2-year pathway, as outlined in Figure 2. Patients were seen at the Diabetes Centre at City Hospital in Birmingham, UK, in NHS clinics specifically set up for the purpose. The gastroenterologists responsible for EndoBarrier procedures saw the patients in a different clinic in the same setting. The insertion and removal procedures were carried out in an interventional radiology or fluoroscopic screening room by the two gastroenterologists with the support of an anaesthetist and operating department practitioner, endoscopy nursing staff trained in EndoBarrier insertion and removal techniques, and a radiographer. The first EndoBarrier implantation in the NHS service was in October 2014 and the last one in November 2017, with the last EndoBarrier being removed in November 2018.

### Participants

All patients had type 2 diabetes, were aged between 28 and 70 years, BMI >30 kg/m<sup>2</sup> and had tried diet, lifestyle and medications including GLP-1 receptor agonists and, once available, SGLT2 inhibitors if within licence. Thus, the only options left for them were to start insulin, increase insulin further if already on insulin, or have bariatric/metabolic surgery or alternative procedures not yet available on the NHS. HbA<sub>1c</sub> >58 mmol/mol (7.5%) was generally required. Lower HbA<sub>1c</sub> was acceptable only if patients were already established on insulin and the diabetologist considered that the patient's insulin treatment to maintain the lower HbA<sub>1c</sub> was contributing significantly to the obesity. Patients were considered for EndoBarrier based on HbA<sub>1c</sub> assessed at the screening visit. If at that visit they fulfilled the criteria and they wished to proceed, they were then assessed by the gastroenterologists who would insert the EndoBarrier and, if they were accepted by them, they went onto a waiting list.

**Figure 2.** Comprehensive 2-year patient pathway for NHS EndoBarrier service

During the interval between the initial visits and EndoBarrier implantation, in some patients HbA<sub>1c</sub> improved to  $\leq 58$  mmol/mol (7.5%). Such patients were given the previously offered EndoBarrier treatment. Patients taking aspirin or other antiplatelet medication that could not safely be stopped were excluded. Patients were required to agree to take high-dose proton pump inhibitors (omeprazole 40 mg twice daily) throughout the period of EndoBarrier implantation. *Helicobacter pylori* was tested by stool antigen test and was checked before the patients began their omeprazole. Those who were screen positive were excluded unless this was eradicated using a *H. pylori* eradication protocol.

### Variables

We recorded baseline age, sex, ethnicity, smoking history, diabetes duration and medications. At baseline and at 3-monthly intervals during the period following EndoBarrier insertion we measured HbA<sub>1c</sub>, weight and BMI, systolic blood pressure, cholesterol, HDL cholesterol, cardiovascular risk as assessed by the UKPDS Risk Engine v2,<sup>21</sup> alanine aminotransferase (a marker of fatty liver disease),<sup>9</sup> diabetes medications – including insulin total daily dose if applicable. We chose alanine aminotransferase as a marker of fatty liver disease because it is measured in routine clinical practice and because, in our REVISE-Diabetesity research study, we used MRI scanning to measure reduction of liver fat in response to EndoBarrier and found that a fall in alanine aminotransferase reflected the reduction in fat demonstrated by the MRI scan.<sup>9</sup> Side effects were recorded, in particular gastrointestinal side effects and any serious adverse events leading to early removal of the EndoBarrier. Patient satisfaction was assessed using the NHS Friends and Family Test.<sup>22</sup> Weight and

height were measured on standard outpatient equipment. Biochemistry parameters were measured in the pathology department at City Hospital.

### Sources of bias

As we were auditing routine practice, we could not interfere with standard care which might have impacted on the results – for example, medications for other conditions such as steroids for inflammatory conditions or medications for mental health. There was no control group for comparison and there was no blinding.

### Study size

It was our intention to study all patients we treated with EndoBarrier in the same way. After EndoBarrier insertion in 62 such patients, the CE mark for EndoBarrier was suspended (November 2017)<sup>23</sup> and we present here the data on all 62 patients up until the last device removal in November 2018.

### Statistical methods

The impact of EndoBarrier on the parameters measured at follow-up was assessed by comparing the parameter in the last value measured prior to removal with the baseline value using a paired Student t-test. As all patients had to attend in order to have the EndoBarrier removed, removal data were obtained in all patients except one whose explantation occurred within 3 weeks of insertion.

### Results

Between October 2014 when the service commenced and November 2017 when the last EndoBarrier was inserted, 62/174

**Table 1** Reasons why 112/174 (64%) patients referred did not receive EndoBarrier treatment

Reason for not having EndoBarrier	n (%)
Aspirin, clopidogrel or anticoagulants for cardio, cerebral or peripheral vascular disease	20 (17.9)
Patient had not tried a GLP-1 receptor agonist	17 (15.2)
Patient declined	17 (15.2)
HbA <sub>1c</sub> too low	14 (12.5)
Patient did not have diabetes	10 (8.9)
Considered unsuitable by gastroenterologists	7 (6.3)
Lost weight by diet	7 (6.3)
Did not attend	6 (5.4)
Lived too far away	2 (1.8)
Referred to End-OSA research study*	2 (1.8)
Too ill	2 (1.8)
Type 1 diabetes	2 (1.8)
Anaemia	1 (0.9)
Bariatric surgery preferred	1 (0.9)
Funding problems	1 (0.9)
Needs to be on non-steroidal anti-inflammatory agents	1 (0.9)
Previous bariatric intervention	1 (0.9)
Patient died before attending clinic	1 (0.9)

\*EndoBarrier in diabetes with obstructive sleep apnoea  
ISRCTN33788132 <https://doi.org/10.1186/ISRCTN33788132>

(36%) referrals to the service were accepted for EndoBarrier treatment after reference to eligibility criteria and full informed consent involving the patient concerned. Table 1 shows the reasons why 112 of the 174 patients (64%) referred did not receive EndoBarrier treatment. Of the 62 patients accepted for EndoBarrier, one failed to comply with mandatory dietary advice to only eat puréed food during the second week after EndoBarrier insertion, which led to gastrointestinal haemorrhage so he had the EndoBarrier removed (patient 1, Table 5). Table 2 shows the baseline characteristics of the remaining 61 patients (age 51.4±7.2 years, 54.1% male, 57.4% European, diabetes duration 12.0 (8.0–19.5) years, 57.4% insulin-treated, BMI 41.9±7.4 kg/m<sup>2</sup>).

Table 3 shows the main outcomes during the period of EndoBarrier implantation. During the period of EndoBarrier treatment mean±SD HbA<sub>1c</sub> fell by 23.7±21.4 mmol/mol from 80.2±22.5 to 56.5±11.5 mmol/mol (p<0.001), weight fell by 15.9±8.5 kg from 122.6±27.9 to 106.7±28.9 kg (p<0.001), systolic blood pressure from 138.5±15.0 to 125.8±14.6 mmHg (p<0.001), cholesterol from 4.7±1.4 to 3.9±0.9 mmol/L (p<0.001) and alanine aminotransferase from 33.2±19.8 to 19.5±11.4 U/L (p<0.001). In the 35 insulin-treated patients, the median (IQR) insulin dose reduced from 100 (54–140) to 40 (0–70) units (p<0.001) with 10/35 (28.6%) discontinuing insulin. As shown in Table 4, there were significant falls (UKPDS Risk Engine v2) in the risk of coronary heart disease (CHD) and stroke, suggesting that EndoBarrier treatment in 100 such patients could prevent eight events of CHD or stroke and save six lives over the 10 years.

**Table 2** Baseline characteristics of 61 patients with implant and explant data

Parameter	n=61
Age (years)	51.4±7.2
Sex (% male)	54.1
Ethnicity:	
% White	57.4
% Afro-Caribbean	16.4
% Asian-Indian	26.2
Smoking:	
% Never smoked	54.1
% Past smoker	26.2
% Current smoker	19.7
Weight (kg)	122.6±27.9
BMI (kg/m <sup>2</sup> )	41.9±7.4
HbA <sub>1c</sub> (mmol/mol)	80.2±22.5
HbA <sub>1c</sub> (%)	9.5±2.1
Diabetes duration (Median[IQR] years)	12.0 (8.0-19.5)
Taking insulin (%)	57.4

**Table 3** The impact of EndoBarrier treatment on mean±SD weight, HbA<sub>1c</sub> and CVD risk factors and alanine aminotransferase (ALT – a liver fat marker) in 61 patients. There were highly significant falls in all parameters involved in CVD risk assessment other than HDL cholesterol which remained unchanged.

Parameter	Baseline	At explant	Difference	p-value
Weight (kg)	122.6±27.9	106.7±28.9	-15.9±8.5	<0.001
BMI (kg/m <sup>2</sup> )	41.9±7.4	36.2±7.6	-5.7±3.2	<0.001
HbA <sub>1c</sub> (mmol/mol)	80.2±22.5	56.5±11.5	-23.7±21.4	<0.001
HbA <sub>1c</sub> (%)	9.5±2.1	7.3±1.1	-2.2±2.0	<0.001
Systolic blood pressure (mmHg)	138.5±15.0	125.8±14.6	-12.7±16.2	<0.001
Cholesterol (mmol/L)	4.7±1.4	3.9±0.9	-0.86±1.13	<0.001
HDL (mmol/L)	1.13±0.27	1.10±0.30	0.04±0.22	0.135
ALT (U/L)	33.2±19.8	19.5±11.4	-13.7±20.1	<0.001
Insulin daily dose (median [IQR] n=35)*	100(60-135)	40(0-70)	-60	<0.001

\*10 of the 35 (28.6%) patients were able to discontinue insulin

### Early removal

Ten of the 62 patients implanted with EndoBarrier (16%) required early removal, four for gastrointestinal haemorrhage, two for liver abscess, one for another abdominal abscess and three for gastrointestinal symptoms. Table 5 gives the details of these 10 cases. In nine of these cases the EndoBarrier was retained for at least 2 months (median 273 days, range 61–336 days). In several cases there were issues with compliance which led to early removal, removals which may have been avoided with better compliance with dietary and/or medication advice (Table 5). All made a full recovery following device removal and most derived benefit despite the setback. Indeed, in the nine early removal patients who adhered to

**Table 4** EndoBarrier impact on 10-year CV risk as assessed by the UKPDS risk engine

	Before EndoBarrier	At EndoBarrier removal	p-value	Absolute risk reduction	Cases saved (out of 100)	Numbers needed to treat
CHD	15.8±11.8	9.0±6.0	<0.001	-6.8±7.6	6.8	14.7
Fatal CHD	11.4±10.1	5.6±4.7	<0.001	-5.7±6.7	5.7	17.5
Stroke	5.90±4.71	4.84±3.70	<0.001	-1.06±1.50	1.06	94.3
Fatal stroke	0.94±0.89	0.61±0.52	<0.001	-0.33±0.54	0.33	303.0

**Interpretation:**

According to UKPDS risk engine about **8 patients out of 100** will not have a coronary heart disease or stroke event over the next 10 years because of EndoBarrier treatment about **6 lives will be saved**

**Table 5** Serious adverse events (SAE) leading to early removal of EndoBarrier (EB)

ID	Age	Sex	Ethnicity	Duration diabetes (yrs)	EB in situ (days)	Weight loss (kg)	Fall in HbA <sub>1c</sub> (mmol/mol[%])	Change in insulin dose (IU)	SAE	SAE potentially avoidable?	Comment
1	49.5	M	Asian/Indian	20	18	3.2 (from 109.2 to 106.0)	NA	NA	GI bleed	Yes	Reverted to normal eating instead of pureed food in second week - caused GI bleed
2	38.8	F	Asian/Indian	4	61	8.2 (from 96.8 to 88.6)	36 (3.3) (from 98 [11.1] to 62 [7.8])	NA	GI bleed	No	Vomiting for several weeks then noticed blood in vomit
3	46.5	M	Asian/Indian	14	75	9.6 (from 108.2 to 98.6)	62 (5.6) (from 109 [12.1] to 47 [6.5])	140 to 30	GI bleed	Yes	Stopped take omeprazole - failed to get repeat prescription
4	48.8	M	White	4	103	5.8 (from 140.6 to 134.8)	10 [0.9] (from 57* [7.4] to 47 [6.5])	NA	GI bleed	No	Presented with haematemesis and melaena. No sign of bleeding at endoscopy but EndoBarrier had migrated
5	50.9	M	Afro-Caribbean	9	214	18.4 (from 159.8 to 141.4)	1 (0.1) (from 55* [7.2] to 54 [7.1])	NA	Liver abscess	Possibly**	Treated in ICU for suspected pneumonia without staff realising the liver abscess possibility. Diagnosis made as chance finding on a CT scan
6	58.0	F	White	33	273	18.6 (from 118.8 to 100.2)	27 (2.5) (from 93 [10.7] to 66 [8.2])	82 to 62	Other abscess	No	Abscess (not in the liver) thought to be due to small perforation of the bowel in relation to EndoBarrier
7	49.6	F	White	4	294	12.8 (from 107.6 to 94.8)	2 (0.2) (from 55 [7.2] to 53 [7])	54 to 0	GI symptoms	No	After 10 months she had achieved sufficient benefit from EndoBarrier and asked for removal when GI symptoms worsened.
8	61.9	F	White	15	294	23.6 (from 104.6 to 81.0)	7 (0.6) (from 63 [7.9] to 56 [7.3])	28 to 0	Symptoms	Yes	Swallowed a piece of unchewed steak at celebratory meal - it blocked EndoBarrier which migrated
9	47.6	F	White	2	313	11.6 (from 84.6 to 73.0)	44 (4.1) (from 93 [10.7] to 49 [6.6])	NA	Symptoms	Yes	Copious lumps of food blocked EndoBarrier which migrated
10	44.4	F	White	12	336	13.8 (from 113.0 to 99.2)	34 (3.1) (from 85 [9.9] to 51 [6.8])	NA	Liver abscess	Possibly**	Liver abscess found after 11 months EndoBarrier - history of illness not known

NA = Not applicable.


\* At screening visit HbA<sub>1c</sub> was 67 and 74 mmol/mol respectively for these patients and, though they managed to reduce HbA<sub>1c</sub> in preparation for receiving EndoBarrier, both wished to proceed in view of their weight and other co-morbidities.

\*\* Early removal for this complication may be avoided in the future with increased awareness and vigilance amongst clinicians and patients as is being exercised in the current US FDA pivotal study.<sup>30</sup>

the dietary recommendations for the first 2 weeks (table 5, patients 2–10), mean±SD HbA<sub>1c</sub> fell by 24.8±21.2 mmol/mol from 78.7±21.2 to 53.9±6.7 mmol/mol (p=0.008) and weight fell by 13.6±5.7 kg from 114.9±22.8 to 101.3±22.8 kg (p<0.001). Thus, the improvements experienced by the early removal patients were not greatly different from those of the full cohort.

**Tolerability**

Aside from early removal due to gastrointestinal bleed or abscesses, 51/54 patients tolerated the device for its full planned year. In the remaining three cases who experienced gastrointestinal symptoms, the device was removed earlier than planned (Table 5).

**Figure 3.** Patient satisfaction – NHS Friends and Family Test

### Patient satisfaction

It was our experience at clinic visits that patients typically reported a considerable increase in fitness and well-being, although we did not have any formal measure of this in our audit. Figure 3 shows the results from the NHS Friends and Family Test<sup>22</sup> in response to the question: “How likely would you be to recommend this treatment to friends and family?”. The benefits to the patients concerned are most readily appreciated from the pictorial examples and from interviews with them, both of which can be viewed online.<sup>24,25</sup> These are typical of the group as a whole.

## Discussion

### Key results

In this first NHS service, EndoBarrier was used in patients with long-standing poorly controlled diabetes and obesity that was refractory to standard treatments. EndoBarrier resulted in considerable weight loss (mean 15.9 kg), improvement in glycaemic control (mean 23.7 mmol/mol from 82.2 to 56.5 mmol/mol), significant reduction in a marker of fatty liver, improvement in cardiovascular risk and, for those on insulin, a considerable reduction in insulin dose with nearly 30% discontinuing insulin. As reducing HbA<sub>1c</sub> and blood pressure is associated with improved microvascular outcomes,<sup>26–29</sup> the risk of these was also improved. The device was generally well tolerated and 84% said they would be extremely likely to recommend the treatment to friends and family.

### Limitations

The main limitation of this audit is the lack of a control group. All patients enrolled had a long history of attempts at weight loss and using hypoglycaemic medications known to help with weight loss, such as GLP-1 receptor agonists and SGLT2 inhibitors. Nevertheless, we cannot be sure from this cohort study what contribution there might have been from placebo effect or more intense follow-up. In the current pivotal study with EndoBarrier of the United States Food and Drug Administration (FDA),<sup>30</sup> there is a sham control group who will receive an endoscopic examination without insertion of an EndoBarrier in a double-blind randomised fashion to address this issue. Further

follow-up of the cohort after EndoBarrier explant is being undertaken to assess the extent to which the improvements are sustained. This is important as the benefits of improved cardiovascular and microvascular risk would be dependent on maintenance of improvement after removal of the device.

### Serious adverse events

It is noteworthy that gastrointestinal bleeds occurred early after device insertion (18–103 days). A number of adverse events could potentially have been avoided (Table 5). In the light of our experience, it may be that many such events would in future be avoided in view of the increased education we would give to patients with regard to dietary compliance (avoidance of gastrointestinal haemorrhage [patient 1, Table 5] and gastrointestinal symptoms [patients 8 and 9, Table 5]) and adherence to mandatory medications (proton pump inhibitors [patient 3, Table 5]). In any future service there would be an awareness and focus on prevention of hepatic abscesses; however, as this was an emerging problem during the study, awareness and focus on prevention was not present at the beginning of this study. One of our patients was treated for suspected pneumonia in the Intensive Care Unit without those treating him having any idea that the problem might be hepatic abscess (patient 5, Table 5). Future information carried by patients and improved information given to patients would ensure much earlier detection of such problems. The reason for the occurrence of hepatic abscess as a complication is uncertain, but with the presence of a foreign body in the first part of the small intestine which becomes covered with bacteria, it is not unreasonable to presume that portal bacteraemia might occur, sometimes leading to infection in the liver. Strategies for reduction of this complication are being considered, including antibiotic prophylaxis, reduction of proton pump inhibitors and shortening of the treatment phase. In the current FDA pivotal trial,<sup>30</sup> daily temperature monitoring is being proposed with monthly white blood cell and C-Reactive Protein assessment in an effort to identify – and hopefully treat – without removal of the EndoBarrier, any infection very early. There is a report of a patient with well-established hepatic abscess successfully treated with antibiotics without removal of the device;<sup>31</sup> this patient was detected much later than it is hoped will occur in the FDA pivotal trial.

### Interpretation

All the patients with early removal because of serious adverse events made a full recovery and most derived considerable benefit. Indeed, the mean HbA<sub>1c</sub> fall of 24.8 mmol/mol and weight loss of 13.6 kg from 114.9±22.8 to 101.3±22.8 kg ( $p<0.001$ ) are improvements experienced by the early removal group that were not greatly different from those of the full cohort. EndoBarrier treatment requires only a relatively simple endoscopy procedure and it is noteworthy that endoscopy units and skilled endoscopists are ubiquitous throughout the NHS. In the context of the diabetes pandemic, there is a need for simpler treatments that are less invasive than bariatric surgery for the many patients with obesity and poorly controlled diabetes despite lifestyle and pharmaceutical interventions. Therefore, EndoBarrier deserves further investigation as potential treatment for wider use in refractory



## Key messages

- In people with obesity, poor glycaemic control and long duration of diabetes, EndoBarrier led to considerable improvement in weight, and microvascular risk as indicated by improvement in blood pressure and glycaemic control. There was a significant reduction in cardiovascular risk as assessed by the UKPDS risk engine.
- There was a reduction in a marker of fatty liver and in those on insulin, a considerable reduction in required insulin dose with 30% discontinuing insulin
- All patients requiring early removal for serious adverse events or side effects (16%) recovered fully and despite early removal derived benefit. In many, such problems could be avoided in the future by improved education and vigilance
- Patient satisfaction levels were high and these results from the first NHS EndoBarrier service are encouraging for EndoBarrier as a treatment for patients with long duration diabetes and obesity who remain with poor glycaemic control despite other diabetes treatments

diabesity, especially bearing in mind cardiovascular and microvascular risk to the patients if they are not given additional treatment.

### Generalisability

Future use of EndoBarrier within the NHS is dependent on restoration of its CE mark, which was not renewed in November 2017 by the notified body at the time for reasons that are not entirely clear.<sup>23</sup> The makers of EndoBarrier are now working with a new notified body with a view to imminent restoration of the CE mark.<sup>32</sup> Endoscopy units are ubiquitous throughout the NHS, as are skilled endoscopists. Patients with refractory uncontrolled diabesity are also abundant throughout the NHS and therefore, should the CE mark be restored, it would be relatively easy to make EndoBarrier widely available. The lessons we have learned with regard to measures to minimise serious adverse events would also be useful to future services.

**Conflict of interest** REJR: speaker fees and/or consultancy fees and/or educational sponsorships from AstraZeneca, BioQuest, GI Dynamics, Janssen, Novo Nordisk, Sanofi-Aventis and Takeda. Other authors none

**Funding** None

**Acknowledgement** The success of the project was down to a team effort with many people involved. We would like thank in particular all of the endoscopy, anaesthetic and diabetes staff involved in the care of these patients, and Dominic Jackson from Elemental Healthcare Limited who supported with his long standing expertise with EndoBarrier. Special thanks to Melanie Wyres who was the administrative rock at the core of the project. And finally thanks to our chief executive, Toby Lewis, for his crucial support in getting this innovative new service established in our busy hospital despite so many other priorities, and for facilitating negotiations with the local CCG.

## References

1. The EndoBarrier Gastrointestinal Liner with Delivery System: instructions for use. GID part number 50-10-00552 Rev N. <http://gidynamics.com/wp-content/uploads/2017/09/50-10-00552-Rev-N-IFU-EB-GI-Liner-with-Delivery-System.pdf> (accessed 10 September 2019)
2. de Jonge C, Rensen SS, Verdam FJ, *et al.* Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. *Obes Surg* 2013;**23**:1354–60. <https://doi.org/10.1007/s11695-013-0921-3>
3. Betzel B, Homan J, Aarts EO, *et al.* Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. *Surg Endosc* 2017;**31**:2881–91. <https://doi.org/10.1007/s00464-016-5299-6>
4. Kaválková P, Mráz M, Trachta P, *et al.* Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus. *J Endocrinol* 2016; **231**:11–22. <https://doi.org/10.1530/JOE-16-0206>
5. Koehestanie P, Dogan K, Berends F, *et al.* Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. *Endosc Int Open* 2014; **2**(1):E21–E27. <https://doi.org/10.1055/s-0034-1365222>
6. Jirapinyo, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. *Diabetes Care* 2018;**41**(5):1106–15. <https://doi.org/10.2337/dc17-1985>
7. Sen Gupta P, Drummond RS, McGowan BM, *et al.* One year efficacy, safety and tolerability of duodenal exclusion using Endobarrier as an adjunct to glucagon-like-peptide-1 (GLP-1) therapy: a randomised controlled trial. *Diabetologia* 2016;**59**(Suppl 1):S272, 569.
8. Ryder REJ. One year efficacy, safety and tolerability of duodenal exclusion using Endobarrier as an adjunct to glucagon-like-peptide-1 (GLP-1) therapy: a randomised controlled trial. ePoster video presentation, European Association for the Study of Diabetes, Munich, 2016. <https://www.easd.org/virtualmeeting/home.html#!resources/one-year-efficacy-safety-and-tolerability-of-duodenal-exclusion-using-endobarrier-as-an-adjunct-to-glucagon-like-peptide-1-glp-1-therapy-a-randomised-controlled-trial-fe99ad0e-0918-4199-9aa7-a423f5555b65> (accessed 10 September 2019)
9. Hayee B, Sen Gupta P, Anderson M, *et al.* Endoscopic proximal intestinal exclusion can improve non-alcoholic fatty liver disease (NAFLD) in patients with diabesity. Proceedings of the Digestive Diseases Week (DDW), San Diego, May 2016.
10. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017.
11. Lim EL, Hollingsworth KG, Aribisala BS, *et al.* Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* 2011;**54**(10):2506–14. <https://doi.org/10.1007/s00125-011-2204-7>
12. Davies MJ. Management of hyperglycaemia in type 2 diabetes: the 2018 consensus report by ADA/EASD Insights from one of the authors. *Br J Diabetes* 2018;**18**:137–40. <https://doi.org/10.15277/bjd.2018.193>
13. Davies MJ, D'Alessio DA, Fradkin J, *et al.* Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2018;**61**(12):2461–98. <https://doi.org/10.1007/s00125-018-4729-5>
14. Riddle MC, Rosenstock J, Gerich J, *et al.* The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 2003;**26**(11):3080–6. <https://doi.org/10.2337/di-acare.26.11.3080>
15. National Institute for Health and Care Excellence (NICE). Insulin therapy in type 2 diabetes. Last revised July 2016. <https://cks.nice.org.uk/insulin-therapy-in-type-2-diabetes#!scenario> (accessed 9 September 2019).
16. Heine RJ, Van Gaal LF, Johns D, *et al.* Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2005;**143**(8):559–69. <https://doi.org/10.7326/0003-4819-143-8-200510180-00006>
17. Pories WJ, Caro JF, Flickinger EG, *et al.* The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. *Ann Surg* 1987;**206**:316–23. <https://doi.org/10.1097/0000658-198709000-00009>
18. Rubino F, Forgione A, Cummings DE, *et al.* The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small

- intestine in the pathophysiology of type 2 diabetes. *Ann Surg* 2006; **244**:741–9. <https://doi.org/10.1097/01.sla.0000224726.61448.1b>
19. Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass vs gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. *Int J Obes (Lond)* 2010; **34**:462–71. <https://doi.org/10.1038/ijo.2009.254>
  20. The ABCD EndoBarrier Worldwide Registry. <https://abcd.care/worldwide-endobarrier-registry> (accessed 8 November 2019).
  21. The UKPDS Risk Engine v2.0. <https://www.dtu.ox.ac.uk/riskengine/> (accessed 10 September 2019).
  22. NHS England. Friends and Family Test. <https://www.england.nhs.uk/fft/> (accessed 10 September 2019).
  23. GI Dynamics. GI Dynamics receives CE Certificate of Conformity withdrawal notice for EndoBarrier. <https://gidynamics.com/2017/11/12/gi-dynamics-receives-ce-certificate-conformity-withdrawal-notice-endobarrier/> (accessed 11 September 2019).
  24. Birmingham EndoBarrier Treated Patients. Pictures obtained with written consent for online publication. [http://www.diabetologists-abcd.org.uk/Endobarrier/Birmingham\\_Endobarrier\\_patients.pdf](http://www.diabetologists-abcd.org.uk/Endobarrier/Birmingham_Endobarrier_patients.pdf) (accessed 1 November 2019).
  25. Interviews with Birmingham EndoBarrier Treated patients. Video footage obtained with written consent for online publication. <https://tinyurl.com/y4pwwokc> (accessed 1 November 2019).
  26. United Kingdom Prospective Diabetes Study (UKPDS). Main Trial. <https://www.dtu.ox.ac.uk/ukpds/> (accessed 10 September 2019).
  27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998; **317**:703–13. <https://doi.org/10.1136/bmj.317.7160.703>
  28. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998; **317**:713–20. <https://doi.org/10.1136/bmj.317.7160.713>
  29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; **352**(9131):837–53. [https://doi.org/10.1016/S0140-6736\(98\)07019-6](https://doi.org/10.1016/S0140-6736(98)07019-6)
  30. GI Dynamics. A randomized, multi-center, pivotal efficacy and safety study evaluating the EndoBarrier® system for glycemic improvement in patients with inadequately controlled type 2 diabetes and obesity (FDA IDE STEP-1 study). <https://gidynamics.com/2018/08/12/gi-dynamics-announces-fda-approval-endobarrier-pivotal-trial/> (accessed 10 September 2019).
  31. Drummond RS, Timmons J, Talla M, Sen Gupta P, Ryder REJ. Liver abscess secondary to a duodenal-jejunal bypass liner (DJBL) successfully treated with antibiotics but without removal of the device. Proceedings of the ABCD Spring Meeting, 2018. <https://abcd.care/resource/liver-abscess-secondary-duodenal-jejunal-bypass-liner-djbl-successfully-treated-0> (accessed 27 November 2019).
  32. GI Dynamics Announces Selection of New Notified Body. <https://gidynamics.com/2018/10/05/gi-dynamics-announces-selection-new-notified-body/> (accessed 5 November 2019).



FreeStyle  
Libre  
FLASH GLUCOSE MONITORING SYSTEM

**PATIENTS  
CAN  
DO IT  
WITHOUT LANCETS<sup>1</sup>**



Digital health tools that work together  
for seamless diabetes management



REVEAL

Healthcare providers have secure, online access to glucose insights<sup>2,3</sup>



SCAN

Patients can conveniently check their glucose using their phone<sup>4,5</sup>



CONNECT

Caregivers can remotely monitor their loved ones<sup>6</sup>

For more information, please visit  
[www.FreeStyleDiabetes.co.uk](http://www.FreeStyleDiabetes.co.uk)



life. to the fullest.®

Abbott

1. Scanning the sensor does not require lancets. 2. LibreView minimum system requirements: Safari release 10.1, Internet Explorer 11, Firefox release 32.0, or Chrome release 37.0, installed on a computer running Mac OS X Yosemite (10.10), Windows 7 SP1, Windows 8.1, or Windows 10 Anniversary update. LibreView Device Drivers are installed in order to upload data from a device connected to the computer. Refer to the LibreView Quick Start Guide for additional information. 3. The user of the FreeStyle LibreLink app must be connected to the Internet in order for their glucose data to automatically upload to LibreView. 4. The FreeStyle LibreLink app is compatible with NFC-enabled smartphones running Android OS 5.0 or later and with iPhone 7 and later running OS 11 and later. Use of FreeStyle LibreLink requires registration with LibreView, a service provided by Abbott and Newyu, Inc. 5. The FreeStyle LibreLink app and the FreeStyle Libre reader have similar but not identical features. A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the FreeStyle LibreLink app or when symptoms do not match the app readings. The FreeStyle Libre sensor communicates with the FreeStyle Libre reader that started it or the FreeStyle LibreLink app that started it. A sensor started by the FreeStyle Libre reader will also communicate with the FreeStyle LibreLink app. 6. LibreLinkUp is a mobile application, developed and provided by Newyu, Inc. Use of LibreLinkUp and FreeStyle LibreLink requires registration with LibreView, a service provided by Abbott and Newyu, Inc. The LibreLinkUp mobile app is not intended to be a primary glucose monitor; home users must consult their primary device(s) and consult a healthcare professional before making any medical interpretation and therapy adjustments from the information provided by the app. © 2019 Abbott. FreeStyle, Libre, and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions. ADC-16282 v1.0 10/19